You mentioned from this reading/article that levadopa is in effective in MSA - P candidates because 'the pre and post synaptic nerves of the dopaminergic pathways are impaired'.
With ATH434, as you would have read, is aiming to go deeper and prevent cellular/nerve damage by removing excess ferrous iron that destroys/clumps asynucliens together within cells, causing cellular death/atrophy, which would also cause disruption of the synaptic gap communication.
Therefore, if ATH434 can step in before this, by removing the excess iron, thus preventing clumping of the asynucliens, than there would be no cellular destruction/atrophy/death, therefore preserving nerve pathways. Which would therefore allow other drugs to work theoretically more effectively.
I've provided a pic, to show asynuclien involvement way before.
ATH Price at posting:
0.3¢ Sentiment: Hold Disclosure: Held
(20min delay)